Your browser doesn't support javascript.
loading
Quantification of insulin receptor mRNA splice variants as a diagnostic tumor marker in breast cancer.
Aljada, Ahmad; Saleh, Ayman M; Al-Aqeel, Suliaman M; Shamsa, Heba Bani; Al-Bawab, Ahmad; Al Dubayee, Mohammed; Ahmed, Altayeb Abdalla.
Affiliation
  • Aljada A; Department of Basic Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Kingdom of Saudi Arabia.
  • Saleh AM; King Abdullah International Medical Research Center (KAIMRC), National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.
  • Al-Aqeel SM; Department of Basic Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Kingdom of Saudi Arabia.
  • Shamsa HB; King Abdullah International Medical Research Center (KAIMRC), National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.
  • Al-Bawab A; Department of Basic Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Kingdom of Saudi Arabia.
  • Al Dubayee M; King Abdullah International Medical Research Center (KAIMRC), National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.
  • Ahmed AA; Department of Basic Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Kingdom of Saudi Arabia.
Cancer Biomark ; 15(5): 653-61, 2015.
Article in En | MEDLINE | ID: mdl-26406954
ABSTRACT

BACKGROUND:

The mature human insulin receptor (INSR) has two isoforms The A isoform and the B isoform. INSR upregulation has been suggested to play a role in cancer.

OBJECTIVE:

To establish quantitative PCR method for INSR transcript variants and examine their differential expression as a diagnostic tumor marker in breast cancer.

METHODS:

The differential expression of IR-A and IR-B were evaluated by TaqMan qRT-PCR assay in the commercially available Breast Cancer Disease cDNA and Cancer Survey cDNA arrays.

RESULTS:

The mRNA expression levels of IR-A was statistically significantly higher in breast cancer when compared to normal breast tissue while IR-B mRNA expression was down regulated significantly in breast cancer. Stratification of patients into groups according to metastatic stages indicated statistically significantly higher levels of IR-A mRNA in clinical stage (CS)-IV, and lower IR-B levels in CS-IIA, CS-IIIB and CS-IIIC. However, IR-AIR-B ratio showed a statistically significant increase in all stages. Cancer Survey cDNA array demonstrated lower levels of IR-B mRNA in breast adenocarcinoma, liver carcinoma and lung carcinoma only while IR-A expression was significantly altered in kidney carcinoma without any significant differences in IR-AIR-B ratios.

CONCLUSIONS:

The results demonstrate an increased IR-AIR-B ratio in all clinical stages of breast cancer. Thus, IR-AIR-B ratio may have a diagnostic biomarker utility in breast cancer.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, Insulin / Biomarkers, Tumor / Antigens, CD / Protein Isoforms Type of study: Diagnostic_studies Limits: Female / Humans Language: En Journal: Cancer Biomark Journal subject: BIOQUIMICA / NEOPLASIAS Year: 2015 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, Insulin / Biomarkers, Tumor / Antigens, CD / Protein Isoforms Type of study: Diagnostic_studies Limits: Female / Humans Language: En Journal: Cancer Biomark Journal subject: BIOQUIMICA / NEOPLASIAS Year: 2015 Document type: Article